Abstract
Mucopolysaccharidoses (MPS) are inherited metabolic disorders, caused by mutations leading to dysfunction of one of enzymes involved in degradation of glycosaminoglycans (GAGs) in lysosomes. Due to their impaired degradation, GAGs accumulate in cells of patients, which results in dysfunction of tissues and organs, including the heart, respiratory system, bones, joints and central nervous system. Depending on the kind of deficient enzyme, 11 types and subtypes of MPS are currently recognized. Although enzyme replacement therapy has been developed for 3 types of MPS (types I, II and VI), this treatment was found to be effective only in management of somatic symptoms. Since all MPS types except IVA, IVB and VI are characterized by various problems with functioning of the central nervous system (CNS), a search for effective treatment of this system is highly desirable. Recent discoveries suggested that substrate reduction therapy may be an efficient method for treatment of MPS patients, including their CNS. In this review, different variants of this therapy will be discussed in the light of recently published reports.
Keywords: mucopolysaccharidoses, lysosomal storage diseases, substrate reduction therapy, gene expression-targeted isoflavone therapy, siRNA, shRNA, glycosaminoglycans (GAGs), large biomolecules, central nervous system (CNS), neurodegenerative diseases, genetic disorders, symptomatic treatment of patients, Sanfilippo disease, hematopoietic stem cells', untreated animals, cognitive functions
Current Pharmaceutical Biotechnology
Title: Substrate Reduction Therapies for Mucopolysaccharidoses
Volume: 12 Issue: 11
Author(s): Joanna Jakobkiewicz-Banecka, Ewa Piotrowska, Magdalena Gabig-Ciminska, Elzbieta Borysiewicz, Monika Slominska-Wojewodzka, Magdalena Narajczyk, Alicja Wegrzyn and Grzegorz Wegrzyn
Affiliation:
Keywords: mucopolysaccharidoses, lysosomal storage diseases, substrate reduction therapy, gene expression-targeted isoflavone therapy, siRNA, shRNA, glycosaminoglycans (GAGs), large biomolecules, central nervous system (CNS), neurodegenerative diseases, genetic disorders, symptomatic treatment of patients, Sanfilippo disease, hematopoietic stem cells', untreated animals, cognitive functions
Abstract: Mucopolysaccharidoses (MPS) are inherited metabolic disorders, caused by mutations leading to dysfunction of one of enzymes involved in degradation of glycosaminoglycans (GAGs) in lysosomes. Due to their impaired degradation, GAGs accumulate in cells of patients, which results in dysfunction of tissues and organs, including the heart, respiratory system, bones, joints and central nervous system. Depending on the kind of deficient enzyme, 11 types and subtypes of MPS are currently recognized. Although enzyme replacement therapy has been developed for 3 types of MPS (types I, II and VI), this treatment was found to be effective only in management of somatic symptoms. Since all MPS types except IVA, IVB and VI are characterized by various problems with functioning of the central nervous system (CNS), a search for effective treatment of this system is highly desirable. Recent discoveries suggested that substrate reduction therapy may be an efficient method for treatment of MPS patients, including their CNS. In this review, different variants of this therapy will be discussed in the light of recently published reports.
Export Options
About this article
Cite this article as:
Jakobkiewicz-Banecka Joanna, Piotrowska Ewa, Gabig-Ciminska Magdalena, Borysiewicz Elzbieta, Slominska-Wojewodzka Monika, Narajczyk Magdalena, Wegrzyn Alicja and Wegrzyn Grzegorz, Substrate Reduction Therapies for Mucopolysaccharidoses, Current Pharmaceutical Biotechnology 2011; 12 (11) . https://dx.doi.org/10.2174/138920111798376932
DOI https://dx.doi.org/10.2174/138920111798376932 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Hidden Impact of COVID-19 on Sexual and Reproductive Health and Rights of Women in India
Current Women`s Health Reviews Zinc and its Specific Transporters as Potential Targets in Airway Disease
Current Drug Targets Lipid Nanocarriers and Molecular Targets for Malaria Chemotherapy
Current Drug Targets Hormone Responsive Breast Cancer and BRCA1 Mutation: Mechanism, Regulation and Iron-mediated Effects
Current Pharmaceutical Biotechnology Nitric Oxide and Teratogenesis: An Update
Current Pharmaceutical Design Vaccine Therapy Update for Pregnant, Immunocompromised, and Chronic Diseases Patients
Recent Patents on Inflammation & Allergy Drug Discovery Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6- Phosphate Dehydrogenase Deficiency
Current Drug Safety From the Multifactorial Nature of Alzheimer`s Disease to Multitarget Therapy: The Contribution of the Translational Approach
Current Topics in Medicinal Chemistry The Use of Microarrays to Study Childhood Developmental Brain Disorders
Current Genomics Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology The role of vitamin D towards immune tolerance in white adipose tissue (WAT)
Endocrine, Metabolic & Immune Disorders - Drug Targets Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Nuclear Hormone Receptor Signals as New Therapeutic Targets for Urothelial Carcinoma
Current Cancer Drug Targets Membrane Localization of Estrogen Receptors
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Structure, DNA Binding and Cytotoxicity Studies of [Cu(D-glu)(phen)(H2O)]•NO3•2H2O
Letters in Drug Design & Discovery ADAM10 as a Target for Anti-Cancer Therapy
Current Pharmaceutical Biotechnology IAP Proteins Antagonist: An Introduction and Chemistry of Smac Mimetics under Clinical Development
Current Medicinal Chemistry Microarray Technologies for Intracellular Kinome Analysis
Current Medicinal Chemistry Development of Prodrugs for Enzyme-Mediated, Tumor-Selective Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Cognitive Remediation in the Early Course of Schizophrenia: A Critical Review
Current Pharmaceutical Design